PATIENT_ID	START_DATE	STOP_DATE	EVENT_TYPE	TREATMENT_TYPE	SUBTYPE	AGENT	OTHER_SAMPLE_ID	OTHER_PATIENT_ID	CHEMO_CYCLES	COMMENTS	TREATMENT_BEST_RESPONSE	OVERALL_RESPONSE	REASON_FOR_TX_DISCONTINUATION	NOTE	SURGERY_DETAILS	SOURCE	SAMPLE_ID	STATUS	SPECIMEN_TYPE	TREATMENT_DETAILS	SOURCE_LAB	SURGERY	EVENT_DETAILS	DOSAGE	KARNOFSKY_PERFORMANCE_SCORE	SPECIMEN_SITE	TYPE_OF_SURGERY	DIAGNOSTIC_TYPE	DIAGNOSTIC_TYPE_DETAILED	CONCURRENT_CHEMO	MGMT_STATUS	EVENT_TYPE_DETAILED	HISTOLOGY	WHO_GRADE	SOURCE_PATHOLOGY
P-0001442	407		Status											P-0001442-T02-IM5 (no slots available T790M trial went on chemo)				Progression after First Line																	
P-0001442	476		Status															No progression, chemo poorly tolerated																	
P-0001442	17	475	Treatment	Medical Therapy	Target Therapy	Erlotinib								First Line																					
P-0001442	454	476	Treatment	Medical Therapy	Chemotherapy	Cisplatin + Pemetrexed + Bevacizumab								Second Line																					
P-0001442	497	809	Treatment	Medical Therapy	Target Therapy	Omisertinib								Third Line; Ongoing																					
P-0014769	49		Surgery																																
P-0016917	444		Surgery								TREATMENT_BEST_RESPONSE																								
P-0017174	133		Surgery																																
P-0018645	76		Surgery																																